Sanofi ADR

Sanofi researches, manufactures, and markets a broad portfolio of medicines and vaccines, including pediatric vaccines (polio, pertussis, hepatitis), immunology treatments, rare disease therapies, and cancer drugs [Company Overview]. The company operates through partnerships with biotech firms to develop next-generation therapies using AI, protein degradation, and genome editing technologies [Company Overview].

Sanofi is a major French pharmaceutical company with $104.3 billion market cap that develops and sells vaccines, immunology treatments, rare disease therapies, and oncology drugs [Yahoo Finance]. Recent positive phase 2 trial results for efdoralprin alfa in a rare lung disease and AI investments in Alzheimer's research show R&D momentum, though the stock dropped 9% over the past month [Yahoo Finance]. The company is financially healthy with $10.1 billion in free cash flow and a 5.55% dividend yield [Yahoo Finance].

Sanofi is financially healthy with strong cash generation and manageable debt levels [Yahoo Finance].